Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138812 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
A Phase 1 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT02138812 is a Phase 1 study that was terminated before completion, run by Bayer. The registered enrollment target is 69 participants.
The verdict
NCT02138812, a Phase 1 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase II dose (RP2D) of BAY1161909 in combination with paclitaxel in subjects with advanced malignancies.
Interventions
- DRUG Paclitaxel
- DRUG BAY1161909
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2014-05-09 |
| Est. Completion | 2017-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02138812
The ClinicalTrials.gov registry entry for NCT02138812 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT02138812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02138812 about?
NCT02138812 is a clinical study titled "Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel". Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase II dose (RP2D) of BAY1161909 in combination with paclitaxel in subjects with advanced malignancies.
What is the current status of trial NCT02138812?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2014-05-09. Estimated completion is 2017-10-02.
What interventions are being tested in trial NCT02138812?
The interventions under investigation include: Paclitaxel (DRUG), BAY1161909 (DRUG).
Who is sponsoring clinical trial NCT02138812?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.